A Progressive Approach to Open Innovation
“Open innovation is all about sharing and learning. The more you share with the scientific community, the more you learn. You can share questions and ask the wider scientific crowd to solve these problems, or you can provide solutions by sharing high-quality chemical tools to explore new biological disease mechanisms. We actively support both these approaches through our work with public-private partnerships and by applying a variety of crowdsourcing approaches. opnMe is a natural extension of our progressive open innovation strategy which we believe will further the development of collaboration and openness within the drug discovery community and fuel even more scientific creativity and exchange.”
Dr. Adrian J. Carter, Head of Discovery Research Coordination
opnMe – A Catalyst for Scientific Cooperation and Collaboration
opnMe.com provides free and open access to selected pre-clinical compounds for non-clinical investigation purposes. The molecules have been designated either as Molecules to Order (with no associated cost) or Molecules for Collaboration. Scientists interested in molecules for collaboration are invited to submit a research proposal. If the proposal is chosen, the research will be developed together with Boehringer Ingelheim scientists.
The compounds available are a selection of well-characterized, including many best-in-class, tool compounds that have been developed for some of the most relevant molecular targets in medical research. The molecules on opnMe.com have been synthesized according to the highest quality standards. They are provided with a comprehensive data package which will allow the correct interpretation of independent research findings using the tools and which ensures reproducibility of external experiments.
Dr. Clive R. Wood, Head of Discovery Research
References
1 Reichman M and Simpson PB. (2016) Open Innovation in early drug discovery: roadmaps and roadblocks. Drug Discov Today 21, 779–788.